Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessio Cortellini

Showing results (11-20 of 256) with videos related to

Pageof 26
Sort By:
Seminars in Oncology|November 16, 2019
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patientsAlessio Cortellini, Sebastiano Buti, Veronica Agostinelli, et al.
Journal of Thoracic Disease|November 19, 2020
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patientsAlessio Cortellini, Corrado Ficorella, Roberto Crisci, et al.
Thoracic Cancer|December 12, 2018
Family history of cancer and DNA damage response genes: Two sides of the same coin?Alessio Cortellini, Melissa Bersanelli, Corrado Ficorella, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone MattersAlessio Cortellini, Francesco Facchinetti, Lisa Derosa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2020
Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular CancerDavid J Pinato, Petros Fessas, Alessio Cortellini, et al.
Journal of Hepatocellular Carcinoma|August 13, 2021
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future ProspectsAntonio D'Alessio, Lorenza Rimassa, Alessio Cortellini, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinomaDavid J Pinato, Nicola Valeri, Ambreen Muhammed, et al.
Pharmaceutics|June 2, 2021
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS InhibitorsAlice Indini, Erika Rijavec, Michele Ghidini, et al.
Journal of Palliative Medicine|November 2, 2018
"Palliative" or "Supportive": Is It Just a Matter of Word?Giampiero Porzio, Alessio Cortellini, Carla D'Orazio, et al.
Pageof 26

Showing results (11-20 of 256) with videos related to

Sort By:
Pageof 26
Seminars in Oncology|November 16, 2019
A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patientsAlessio Cortellini, Sebastiano Buti, Veronica Agostinelli, et al.
Journal of Thoracic Disease|November 19, 2020
A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patientsAlessio Cortellini, Corrado Ficorella, Roberto Crisci, et al.
Thoracic Cancer|December 12, 2018
Family history of cancer and DNA damage response genes: Two sides of the same coin?Alessio Cortellini, Melissa Bersanelli, Corrado Ficorella, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapyAlessio Cortellini, Melissa Bersanelli, David J Pinato, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2022
Antibiotic Exposure and Immune Checkpoint Inhibitors in Patients With NSCLC: The Backbone MattersAlessio Cortellini, Francesco Facchinetti, Lisa Derosa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2020
Combined PD-1/VEGFR Blockade: A New Era of Treatment for Hepatocellular CancerDavid J Pinato, Petros Fessas, Alessio Cortellini, et al.
Journal of Hepatocellular Carcinoma|August 13, 2021
PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future ProspectsAntonio D'Alessio, Lorenza Rimassa, Alessio Cortellini, et al.
The Lancet. Gastroenterology & Hepatology|May 10, 2021
Therapeutic targeting of VEGFR2 in HBV-associated hepatocellular carcinomaDavid J Pinato, Nicola Valeri, Ambreen Muhammed, et al.
Pharmaceutics|June 2, 2021
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS InhibitorsAlice Indini, Erika Rijavec, Michele Ghidini, et al.
Journal of Palliative Medicine|November 2, 2018
"Palliative" or "Supportive": Is It Just a Matter of Word?Giampiero Porzio, Alessio Cortellini, Carla D'Orazio, et al.
Pageof 26